Search

Background : The 3-year results of the Symplicity HTN-1 trial have shown the superiority of renal sympathetic denervation over drug treatment in patients with resistant hypertension. However, the eficacy of renal sympathetic denervation was not conirmed by Symplicity HTN-3, the irst sham-controlled study. Our objective was to report the safety and eficacy of renal sympathetic denervation using the irrigated rad iofrequency ablation catheter in patients with resistant hypertension. Methods: Twenty-one patients were submitted to the procedure since July 2012, nine of them had a follow-up  12 months and were included in this analysis. The primary endpoint was safety, evaluated by periprocedural adverse events, renal func tion and renal vascular abnormalities at 6 months. Secondary endpoints included changes in blood pressure obtained in ofice and in the number of anti-hyperten sive drugs at 12 months. Results: Mean age was 48.8  11.7 years. In the irst case, there was a renal artery dissection caused by the vascular sheath. There were no cases of thrombosis, renal infarction or death. Serum creatinine levels did not increase during the follow-up period. At 6 months, one case of signiicant renal stenosis without clinical impact was diagnosed. The average reduction in ofice blood pressure was 41.1  33.2/18.6  15.2 mmHg (p = 0.04 for systolic blood pressure and p = 0.08 for diastolic blood pressure) and there was a mean reduction of 2.0  2.3 in the number of anti-hyperten sive drugs at 12 months (p = 0.03). Conclusions: Renal sympathetic denervation using the irrigated radiofrequency ablation catheter proved to be feasible, safe and effective.